# Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma

> **NCT02839681** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 2 (actual)

## Conditions studied

- Lung Neoplasms

## Interventions

- **DRUG:** Anetumab Ravtansine
- **DEVICE:** Blood test

## Key facts

- **NCT ID:** NCT02839681
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07-19
- **Primary completion:** 2018-06-12
- **Final completion:** 2018-07-25
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Due to slow, insufficient accrual.
- **Last updated:** 2019-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02839681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02839681, "Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02839681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*